Objectives: The aim of this study was to determine the MICs of 32 antimicrobial agents for 200 isolates of Rhodococcus equi of animal origin by applying a recently described broth microdilution protocol, and to investigate isolates with distinctly elevated rifampicin MICs for the genetic basis of rifampicin resistance.
Introduction
Rhodococcus equi was first described in 1923 as a causative agent of pyogranulomatous pneumonia in foals. 1 As a pathogen with a high tenacity, R. equi tends to be endemic on horse farms, where it can cause significant economic losses.
2 Besides infections of the respiratory tract of horses, R. equi also plays a role in a wide variety of infections in other animal species, such as pigs, ruminants, cats and dogs, as well as in humans. 1, 2 Although R. equi predominantly causes diseases in immunocompromised humans, it is also capable of infecting healthy people. 3 Antimicrobial agents play an important role in the treatment of R. equi infections.
1,2 CLSI document M24-A2 4 recommends the following antimicrobial agents for primary antimicrobial susceptibility testing of R. equi of human origin: amikacin, amoxicillin/ clavulanic acid, ceftriaxone, ciprofloxacin, clarithromycin, imipenem, linezolid, minocycline, moxifloxacin, trimethoprim/ sulfamethoxazole and tobramycin. Secondary drugs that may be tested include cefepime, cefotaxime and doxycycline. 4 In addition, rifampicin and vancomycin are recommended. 4 In horses, the common treatment for infections caused by R. equi is a combination of rifampicin and a macrolide, e.g. erythromycin, clarithromycin or azithromycin. 5, 6 In this regard, it should be noted that rifampicin, azithromycin and clarithromycin are not approved for use in horses, but may be used via the Animal Medicinal Drug Use Clarification Act (AMDUCA) or similar regulations. 7 It is not There are only a limited number of reports that describe the susceptibility status of R. equi to the therapeutically used antimicrobial agents.
11 -18 A review of the published literature revealed considerable variation in the antimicrobial susceptibility testing conditions (e.g. different media, supplements and incubation times). 19 In order to harmonize the conditions for antimicrobial susceptibility testing of R. equi of animal origin via broth microdilution, a new protocol has been developed, 19 which has recently been approved by the CLSI.
The aim of this study was to apply this protocol to a total of 200 R. equi field isolates collected in North America and Europe and to determine the MICs of 32 antimicrobial agents.
Materials and methods

Clinical isolates
In total, 200 R. equi isolates from different animal species and countries were collected. The vast majority of the isolates (n¼160) originated from horses. This collection also included 13 isolates each from dogs and cats, 5 from cattle, 4 from different reptile species, 2 from goats and 1 each from a budgerigar, a llama and the floor of a veterinary clinic. All isolates originated from diagnostic submissions and were collected between 1989 and 2012 in the USA (n¼100), Germany (n¼90), Denmark (n¼9) and France (n¼1). These isolates were identified in the diagnostic laboratories as R. equi by their colony morphology, positive CAMP test and their biochemical profiles [including results from API Coryne (bioMérieux, Nü rtingen, Germany)]. The species assignment was confirmed for all isolates by a species-specific PCR targeting the choE gene. 20 
Susceptibility testing
MIC values were determined using broth microdilution according to a recently described protocol. 19 For this, custom-made microtitre plates (MCS Diagnostics, Swalmen, The Netherlands) were used. The test ranges for each antimicrobial agent are shown in Table 1 . The test medium was cation-adjusted Mueller-Hinton broth supplemented with 2% (v/v) lysed horse blood. The microtitre plates were incubated at 35+28C in ambient air and the results were read after 24 h. Owing to the fact that the therapeutically important antimicrobial agents rifampicin, azithromycin and clarithromycin were not included in the microtitre plates available, these three antimicrobial agents were tested separately via broth macrodilution using the same test medium and incubation conditions. Staphylococcus aureus ATCC 29213 was used as a quality control (QC) strain.
PCR assays and sequencing
For isolates showing elevated MICs of rifampicin, we developed a new PCR for amplification of an 827 bp region of the rpoB gene. The primers MF (5 ′ -GCTGATCCAGAACCAGATCC-3 ′ ) and MR (5 ′ -TCACGTAGTCGGAGGAGACC -3 ′ ) were designed with Primer3 software (v. 0.4.0) (http://bioinfo.ut.ee/ primer3-0.4.0/) and include all three previously described regions of the rpoB gene, in which rifampicin resistance-mediating mutations have been detected. 8 The PCR was performed with 1 mL of DNA per 24 mL of a PCR mastermix (18.625 mL of purified water, 1.5 mL of dNTP mix, 2.5 mL of 10×PCR buffer, 10 pmol of each of the primers and 0.625 U of Taq polymerase). The amplification was performed with 2 min of initial denaturation at 948C, followed by 30 cycles of denaturation (1 min at 948C), annealing (1 min at 578C) and elongation (1 min at 728C), and a final elongation step of 5 min. The amplification product was completely sequenced (Eurofins MWG GmbH, Ebersberg, Germany), and sequence alignments were performed using ClustalW2 software (http://www.ebi.ac.uk/Tools/msa/ clustalw2/).
Results and discussion
All isolates included in this study were confirmed as R. equi by PCR. The MIC values of the 32 antimicrobial agents for all 200 R. equi isolates are summarized in Table 1 . The results of the QC reference strain S. aureus ATCC 29213 were within the CLSI-approved QC ranges (Table S1 ; available as Supplementary data at JAC Online).
All (Table S2 ; available as Supplementary data at JAC Online). For the isolates from the USA, a comparison between the MICs for the older isolates (1989-99, n¼ 58) and the more recent isolates (2000 -12, n¼ 42) was performed. The MIC distributions were very similar and the MIC 50 and MIC 90 values of the older isolates were the same or differed at maximum by one dilution step from the more recent isolates (Table S3 ; available as Supplementary data at JAC Online). Such a comparison could not be performed for the European isolates since 94 of the 100 isolates were from the period 2000-12. Isolates from sources other than horses also showed comparable results to equine R. equi regarding their MIC distribution and their MIC 50 and MIC 90 values (Table S4 ; available as Supplementary data at JAC Online).
For the vast majority of the tested antimicrobial agents, a normal distribution of the MIC values was observed. However, a small number of R. equi isolates exhibited elevated MIC values for some of the antimicrobial agents. One equine isolate had an apramycin MIC of 8 mg/L, while the other isolates ranged in their MICs from 0.12 to 1 mg/L. A R. equi isolate from a snake showed slightly higher MICs of azithromycin, clarithromycin and erythromycin, of 4, 0.5 and 4 mg/L, respectively. These MICs are one or two steps above the range for the remaining R. equi isolates. However, this isolate's MICs of tilmicosin, tulathromycin and tylosin tartrate were within the usual range. Moreover, six R. equi isolates, all from horses, showed elevated MIC values of rifampicin, which were either 4 -8 mg/L or 64 -256 mg/L.
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The grey-shaded areas represent concentrations not included in the test panels. a MIC values equal to or lower than the lowest concentration tested are given as the lowest concentration tested. Isolates that grew in the highest test concentration are shown in the first grey-shaded right-hand box and the corresponding MIC value is equal to or higher than the respective non-tested concentration. Substitution of Ser by Leu at position 531 was described as a reason for a low-level resistance (MIC 8 mg/L). 8 Two isolates of the present collection showed the same amino acid substitution, but differed in their rifampicin MICs between 8 and 128 mg/L. This observation, in combination with the finding of an isolate with a rifampicin MIC of 8 mg/L, but no mutations in the sequenced region of the rpoB gene, leads to the assumption that there may be mutations in target genes other than rpoB or that completely different mechanisms of rifampicin resistance exist in R. equi. Finally, the substitution of Gln by Leu at position 513 in an R. equi with an MIC of 64 mg/L represents a novel mutation that-to the best of our knowledge-has not yet been found in R. equi, but in Mycobacterium tuberculosis 21, 22 and Haemophilus influenzae. Riesenberg et al.
